Calidi Biotherapeutics Inc Dossier
Financial Snapshot
Revenue, profitability, returns, debt, and capital allocation
Revenue $0TTM through 31 Dec 2025
Net Income -$25.6MTTM through 31 Dec 2025
Free Cash Flow -$21.4MTTM through 31 Dec 2025
Margins
| Current |
|---|
Balance Sheet Health
Debt / Equity0.16x
Current Ratio1.59x
Net Debt-$5Mnet cash position
Cash & Equivalents$5.6M
Quality Metrics
Earnings-Beat Rate25.0%
Dividend
No dividend
Segment Performance
No segment data available.
Filing Detail Members
This section is available to registered members. Create a free account or sign in to unlock the full breakdown.